A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
Total Raised
$180M
ApnimedCelea Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2025
Cambridge, Massachusetts
HQ
Boston, MA
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Celea Therapeutics.